PASSAGE BIO, INC. Operating Income
PASSAGE BIO, INC. (PASG) reported Operating Income of -$8.27 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-09-03
- PASSAGE BIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$8.27M.
- PASSAGE BIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$8.25M.
- PASSAGE BIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$13.85M.
- PASSAGE BIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$8.65M.
- PASSAGE BIO, INC. operating income (loss) for fiscal 2023 was -$108.39M.
- PASSAGE BIO, INC. operating income (loss) for fiscal 2022 was -$138.39M.
- PASSAGE BIO, INC. operating income (loss) for fiscal 2021 was -$185.73M.
- PASSAGE BIO, INC. operating income (loss) for fiscal 2020 was -$112.90M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$8.27M S-4/A · filed 2026-09-03 | -$16.52M S-4/A · filed 2026-09-03 | -$30.37M derived: sum of 3 quarters · filed 2026-09-03 | -$39.02M derived: sum of 4 quarters · filed 2026-09-03 | |
| 2026-03-31 | -$8.25M S-4 · filed 2026-07-21 | -$22.09M derived: sum of 2 quarters · filed 2026-09-03 | -$30.75M derived: sum of 3 quarters · filed 2026-09-03 | -$41.08M derived: sum of 4 quarters · filed 2026-09-03 | |
| 2025-12-31 | -$13.85M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$22.50M derived: sum of 2 quarters · filed 2026-09-03 | -$32.84M derived: sum of 3 quarters · filed 2026-09-03 | -$49.30M S-4/A · filed 2026-09-03 | |
| 2025-09-30 | -$8.65M 10-Q · filed 2025-11-10 | -$18.99M derived: sum of 2 quarters · filed 2026-09-03 | -$35.45M 10-Q · filed 2025-11-10 | -$49.72M derived: sum of 4 quarters · filed 2026-09-03 | |
| 2025-06-30 | -$10.33M S-4/A · filed 2026-09-03 | -$26.79M S-4/A · filed 2026-09-03 | -$41.06M derived: sum of 3 quarters · filed 2026-09-03 | -$61.77M derived: sum of 4 quarters · filed 2026-09-03 | |
| 2025-03-31 | -$16.46M S-4 · filed 2026-07-21 | -$30.73M derived: sum of 2 quarters · filed 2026-09-03 | -$51.43M derived: sum of 3 quarters · filed 2026-09-03 | -$68.81M derived: sum of 4 quarters · filed 2026-09-03 | |
| 2024-12-31 | -$14.27M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$34.97M derived: sum of 2 quarters · filed 2026-09-03 | -$52.35M derived: sum of 3 quarters · filed 2026-09-03 | -$70.40M S-4/A · filed 2026-09-03 | |
| 2024-09-30 | -$20.70M 10-Q · filed 2025-11-10 | -$38.08M derived: sum of 2 quarters · filed 2025-11-10 | -$56.13M 10-Q · filed 2025-11-10 | -$74.58M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$17.38M 10-Q · filed 2025-08-12 | -$35.43M 10-Q · filed 2025-08-12 | -$53.87M derived: sum of 3 quarters · filed 2025-08-12 | -$82.55M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$18.05M 10-Q · filed 2025-05-13 | -$36.50M derived: sum of 2 quarters · filed 2025-05-13 | -$65.17M derived: sum of 3 quarters · filed 2025-05-13 | -$90.56M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$47.12M derived: sum of 2 quarters · filed 2025-03-04 | -$72.51M derived: sum of 3 quarters · filed 2025-03-04 | -$108.39M 10-K · filed 2025-03-04 | |
| 2023-09-30 | -$28.67M 10-Q · filed 2024-11-13 | -$54.06M derived: sum of 2 quarters · filed 2024-11-13 | -$89.94M 10-Q · filed 2024-11-13 | -$118.19M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$25.39M 10-Q · filed 2024-08-08 | -$61.27M 10-Q · filed 2024-08-08 | -$89.52M derived: sum of 3 quarters · filed 2024-08-08 | -$117.04M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$35.88M 10-Q · filed 2024-05-14 | -$64.13M derived: sum of 2 quarters · filed 2024-05-14 | -$91.65M derived: sum of 3 quarters · filed 2024-05-14 | -$131.47M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$28.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$55.77M derived: sum of 2 quarters · filed 2024-03-04 | -$95.58M derived: sum of 3 quarters · filed 2024-03-04 | -$138.39M 10-K · filed 2024-03-04 | |
| 2022-09-30 | -$27.53M 10-Q · filed 2023-11-13 | -$67.34M derived: sum of 2 quarters · filed 2023-11-13 | -$110.15M 10-Q · filed 2023-11-13 | -$161.31M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$39.81M 10-Q · filed 2023-08-07 | -$82.62M 10-Q · filed 2023-08-07 | -$133.78M derived: sum of 3 quarters · filed 2023-08-07 | -$180.88M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$42.81M 10-Q · filed 2023-05-11 | -$93.97M derived: sum of 2 quarters · filed 2023-05-11 | -$141.07M derived: sum of 3 quarters · filed 2023-05-11 | -$189.61M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$51.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$98.26M derived: sum of 2 quarters · filed 2023-03-06 | -$146.79M derived: sum of 3 quarters · filed 2023-03-06 | -$185.73M 10-K · filed 2023-03-06 | |
| 2021-09-30 | -$47.10M 10-Q · filed 2022-11-10 | -$95.64M derived: sum of 2 quarters · filed 2022-11-10 | -$134.57M 10-Q · filed 2022-11-10 | -$173.63M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$48.53M 10-Q · filed 2022-08-04 | -$87.47M 10-Q · filed 2022-08-04 | -$126.52M derived: sum of 3 quarters · filed 2022-08-04 | -$155.15M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$38.93M 10-Q · filed 2022-05-16 | -$77.99M derived: sum of 2 quarters · filed 2022-05-16 | -$106.62M derived: sum of 3 quarters · filed 2022-05-16 | -$133.92M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$39.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$67.69M derived: sum of 2 quarters · filed 2022-03-03 | -$94.99M derived: sum of 3 quarters · filed 2022-03-03 | -$112.90M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$28.63M 10-Q · filed 2021-11-04 | -$55.93M derived: sum of 2 quarters · filed 2021-11-04 | -$73.85M 10-Q · filed 2021-11-04 | -$87.44M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$27.30M 10-Q · filed 2021-08-05 | -$45.22M 10-Q · filed 2021-08-05 | -$58.81M derived: sum of 3 quarters · filed 2021-08-05 | -$70.45M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$17.91M 10-Q · filed 2021-05-05 | -$31.50M derived: sum of 2 quarters · filed 2021-05-05 | -$43.15M derived: sum of 3 quarters · filed 2021-05-05 | -$50.91M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | -$13.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$25.23M derived: sum of 2 quarters · filed 2021-03-03 | -$33.00M derived: sum of 3 quarters · filed 2021-03-03 | -$37.19M 10-K · filed 2021-03-03 | -$4.19M 10-Q · filed 2020-05-11 |
| 2019-09-30 | -$11.64M 10-Q · filed 2020-11-10 | -$19.41M derived: sum of 2 quarters · filed 2020-11-10 | -$23.60M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$7.77M 10-Q · filed 2020-08-13 | -$11.95M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |